Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Libtayo | Lung Cancer

FDA Approves Libtayo as Monotherapy for Advanced NSCLC

Posted on March 1, 2021
Post Views: 624

Libtayo | Lung CancerLung cancer is one of the leading causes of cancer-related deaths worldwide. In the year 2020, an estimated 225,000 new cases were diagnosed in the United States. Also, approximately 84% of all lung cancers are NSCLC, with 75% diagnosed in advanced stages and about 25%-30% expected to test positive in PD-L1 in 50% or more of tumor cells. FDA has approved Libtayo as a monotherapy treatment for non-small cell lung cancer with a programmed death-ligand 1 (PD-1) expression of 50% or more.

This is the first approval for Libtayo after it received approval as the first immunotherapy indicated for patients with advanced basel cell carcinoma and it was approved as first systemic treatment for adults with advanced cutaneous squamous cell carcinoma. The data supporting this approval is based on an analysis of 710 patients who were randomized to receive treatment in phase 3 trial. In this patient population, Libtayo reduced the death risk by 32% compared to chemotherapy. Due to PD-L1 testing issues, additional pre-specified analysis was performed in 563 patients with proven PD-L1 expression of over 50%. This analysis showed that Libtayo reduced death risk by 43% compared to chemotherapy.

Non-Small-Cell Lung Cancer (NSCLC)Naiyer Rizvi, MD, director of thoracic oncology and co-director of cancer immunotherapy at Columbia University Irving Medical Center, said, “The approval of Libtayo to treat first-line advanced non-small lung cancer with high PD-L1 expression means physicians and patients have a potent new treatment option against this deadly disease.”

This approval follows a Priority Review by the FDA which is reserved for medicines that represent significant improvement in safety in treatment of serious conditions. The need for additional therapeutic options in advanced non-small cell lung cancer is clear. Libtayo allows physicians to further optimize treatment of such patients who tumors have high expression of PD-L1.

 

The information shared in this blog is for educational purposes only.

 

 To ensure you don’t miss other Top Stories like these and news on key lung cancer developments, sign up for our free newsletter today.

 

For regular updates follow us on Facebook or Twitter.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,325)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d